Drug Profile

APG 333

Alternative Names: APG-333; PR-018

Latest Information Update: 07 Sep 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Apogee Therapeutics
Class Antiasthmatics; Monoclonal antibodies
Mechanism of Action Thymic stromal lymphopoietin inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Asthma

Most Recent Events

03 Sep 2026 Apogee Therapeutics has been acquired by AbbVie
10 Nov 2025 Pharmacodynamics, pharmacokinetics and adverse events data from phase-I trial in Asthma (In volunteers) released by Apogee Therapeutics
17 May 2025 Pharmacodynamics data from a preclinical Trial in Asthma presented at the 121st International Conference of the American Thoracic Society (ATS-2025)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com